© 2020 MJH Life Sciences and Urology Times. All rights reserved.
© 2020 MJH Life Sciences™ and Urology Times. All rights reserved.
September 28, 2020
Advanced imaging and improvements in biopsy techniques usher in a new paradigm for screening and diagnosis.
September 24, 2020
The addition of the AKT inhibitor ipatasertib to abiraterone acetate and prednisone improved radiographic progression-free survival, with overall survival data still eagerly anticipated.
A new drug application has been submitted to the FDA for TLX591-CDx, a radiopharmaceutical cold kit for the preparation of 68Ga-PSMA-11 injection for PET imaging in prostate cancer.
September 21, 2020
Treatment with AMG 160 showed a manageable safety profile with preliminary efficacy in patients with metastatic castration-resistant prostate cancer.
The PARP inhibitor reduced the risk for death by 31% in men with metastatic castration-resistant prostate cancer, compared with enzalutamide or abiraterone plus prednisone.
September 18, 2020
Based on the findings, investigators recommended that systematic biopsy be performed in patients with negative MRI and in addition to targeted biopsies in men with a positive MRI.
September 16, 2020
The FDA has granted fast track designation to EPI-7386, an oral, highly selective N-terminal domain inhibitor of the androgen receptor for treatment of mCRPC resistant to standard-of-care treatment.
September 11, 2020
Updated results were also reported on other key end points, including time to pain progression, first symptomatic skeletal event, and initiation of chemotherapy.
September 10, 2020
Combination approach could overcome mechanisms that previously led to poor outcomes with single-agent checkpoint inhibition.
Advances in receptor targeted PET imaging continue to refine the identification of metastatic disease.
September 09, 2020
A new analysis supports return to widespread screening.
September 08, 2020
The results suggest the minimally-invasive procedure is an acceptable alternative to immediate surgery or radiation.
September 02, 2020
Mark C. Markowski, MD, PhD, and Emmanuel S. Antonarakis, MD, provide potential explanations for the increased clinical activity of PARP inhibitors in BRCA2- versus BRCA1-mutated prostate cancer.
Personalized approach would reduce the number of biopsies some patients need to receive.
September 01, 2020
The overall risk of cardiac disorders was higher with abiraterone versus enzalutamide.
August 28, 2020
Treatment with the pan-BET bromodomain inhibitor ZEN-3694 plus enzalutamide may re-sensitize patients to androgen receptor–targeting agents.
Survival outcomes are not compromised in men undergoing active surveillance, a recent study finds.
August 27, 2020
The FoundationOne Liquid CDx pan-tumor liquid biopsy examines over 300 cancer-related genes in a patient’s blood sample to inspect for deleterious alterations.
August 24, 2020
In this episode, Samuel J. Peretsman, MD, discusses how to get started with HIFU for prostate cancer and performing robotic prostatectomy following HIFU.
August 20, 2020
Focal therapy using HIFU may be offered as an alternative to the existing modalities of treatment for select patients with all risk profiles of prostate cancer.